• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

    98.65 +2.30 (+2.39%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 782,701
    Open 96.92
    Bid (Size) 93.20 (100)
    Ask (Size) 100.00 (100)
    Prev. Close 96.35
    Today's Range 95.00 - 99.69
    52wk Range 45.91 - 122.20
    Shares Outstanding 66,684,077
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
    Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
    Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
    Via The Motley Fool

    Performance

    YTD
    -6.1%
    -6.1%
    1 Month
    -4.6%
    -4.6%
    3 Month
    -7.4%
    -7.4%
    6 Month
    -0.6%
    -0.6%
    1 Year
    +80.5%
    +80.5%

    More News

    Read More
    News headline image
    Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Prediction: These 3 Stocks Will Crush the Market in 2026 ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    This High-Flying Growth Stock Is Hiding in Plain Sight ↗
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
    Via MarketMinute
    Topics ETFs Economy World Trade
    News headline image
    Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
    Via Stocktwits
    News headline image
    The market is filled with gapping stocks in Thursday's session. ↗
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are moving in today's after hours session ↗
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
    Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
    What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 98.65
    When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 02/24/26 04:00 PM ET
    What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 6.58B
    How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
    Rhythm Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.